Abstract: The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLPP), and/or congenital erythropoietic porphyria (CEP), and related syndromes thereof.
Type:
Grant
Filed:
January 8, 2021
Date of Patent:
November 14, 2023
Assignee:
Disc Medicine, Inc.
Inventors:
Brian Richard MacDonald, Maria Gabriela Beconi, Vu Hong
Abstract: Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating anemias of chronic disease, iron-restricted anemias, and/or conditions associated with anemia.
Type:
Application
Filed:
May 13, 2021
Publication date:
June 15, 2023
Applicants:
Disc Medicine, Inc., Abb Vie Deutschland GmbH & Co. KG, Abb Vie Inc.
Inventors:
Maria Beconi, John Quisel, Brian MacDonald, Steven Robinette, Bernhard Mueller, Andreas Popp, Jennifer M. Perez
Abstract: Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and/or conditions associated with myelofibrosis.
Type:
Application
Filed:
May 13, 2021
Publication date:
June 8, 2023
Applicants:
Disc Medicine, Inc., AbbVie Inc., AbbVie Deutschland GmbH & Co. KG
Inventors:
Maria Beconi, John Quisel, Brian MacDonald, Steven Robinette, Bernhard Mueller, Andreas Popp, Jennifer M. Perez
Abstract: Aspects of the application provide hepcidin antagonists and methods of using the same in treating anemias of chronic disease, iron-restricted anemias, and/or conditions associated with anemia. Accordingly, aspects of the present disclosure relate to treating a subject with high hepcidin levels (e.g., ACD) by inhibiting the BMP signaling pathway (e.g., hemojuvelin-induced BMP signaling pathway) and/or the inflammatory response (e.g., IL-6 mediated inflammatory pathway).
Type:
Application
Filed:
September 25, 2020
Publication date:
November 24, 2022
Applicant:
Disc Medicine, Inc.
Inventors:
John Quisel, Maria Beconi, Steven Robinette, Brian MacDonald
Abstract: Aspects of the application provide hepcidin antagonists and methods of using the same in treating myelofibrosis and/or conditions associated with myelofibrosis. In certain embodiments, methods are provided for treating myelofibrosis, which is generally characterized as a myeloproliferative disease associated with chronic inflammation and progressive marrow fibrosis. Anemia is a major clinical problem in myelofibrosis and is associated with negative outcomes. Such anemia is generally caused by, or associated with, bone marrow failure, splenomegaly and/or functional iron deficiency, which may contribute to inflammation.
Type:
Application
Filed:
September 25, 2020
Publication date:
November 24, 2022
Applicant:
Disc Medicine, Inc.
Inventors:
John Quisel, Maria Beconi, Steven Robinette, Brian MacDonald